Global Utilization News Today

Dual antiplatelet therapy initiated up to 72 hours post-stroke cuts the risk for recurrent stroke but comes with increased bleeding risk, new data from the INSPIRES trial showed.

Researchers have found that ticagrelor-aspirin, compared with clopidogrel-aspirin, is effective and safe for preventing recurrent stroke.

Clinical trials have become too costly and burdensome and its time to reinvent how they are conducted, leading cardiology societies say in a joint opinion.

Ticagrelor alone decreases risk for bleeding in patients at high risk for ischemic or bleeding events who are receiving PCI.